Mobility Tech

Business

Sherwin-Williams Navigates 'Softer for Longer' Market to Post Strong Q4, Eyes Modest 2026 Growth

Despite a persistently muted demand environment, Sherwin-Williams reported robust fourth-quarter earnings, driven by cost discipline and strategic acquisitions. The paint giant forecasts low-to-mid single-digit sales growth for 2026 while reinstating employee benefits, signaling cautious optimism amid ongoing economic headwinds.

Jan 30, 2026

Business

Freedom Capital Trims Li Auto Target Amid Intensifying China EV Price War

Freedom Capital Markets has lowered its price target for Li Auto (NASDAQ: LI) from $34 to $25, citing a mixed quarterly performance and a challenging outlook as China's electric vehicle sector grapples with a fierce price war and softening demand.

Jan 30, 2026

Business

UBS Initiates Coverage on Zai Lab with Buy Rating, Touts Global Ambitions Beyond China

Swiss banking giant UBS has initiated coverage on Zai Lab Limited (NASDAQ: ZLAB) with a bullish 'Buy' rating and a $35 price target, highlighting the biopharma firm's strategic pivot from a China-focused player to a burgeoning global innovation platform with a promising proprietary pipeline.

Jan 30, 2026

Business

Macquarie Trims XPeng Target, Citing Subsidy Cuts and 'Transition Year' Challenges

Investment bank Macquarie has lowered its price target for Chinese EV maker XPeng, pointing to reduced government subsidies and a complex path to profitability as the company expands its model lineup.

Jan 30, 2026

Business

Atour Emerges as a Premium Contender in China's Hotel Wars, Says CLSA

Brokerage firm CLSA initiates coverage on Atour Lifestyle Holdings with an 'Outperform' rating and a $49 price target, highlighting its unique brand ecosystem and asset-light model as key differentiators in a competitive market.

Jan 30, 2026

Business

Morgan Stanley Bullish on Full Truck Alliance, Sees 30%+ Transaction Revenue Surge by 2026

Despite a mixed analyst outlook, Morgan Stanley projects robust growth for Full Truck Alliance's core commission business, even as overall revenue faces headwinds. The digital freight platform's long-term strategy is gaining favor.

Jan 30, 2026

Business

Regulatory Headwinds Cloud Outlook for PDD Holdings Amid Broader China Internet Crackdown

While Morgan Stanley maintains an Overweight rating on PDD Holdings, the firm has removed the e-commerce giant from its Top Picks list, citing heightened regulatory scrutiny and a slower-than-expected consumer recovery in China.

Jan 30, 2026

Business

Genmab Shares Face Target Cut After EPKINLY Trial Misses Survival Goal, But Analysts Keep Faith

H.C. Wainwright has trimmed its price target on Genmab following mixed Phase 3 results for its lymphoma drug EPKINLY, though maintains a Buy rating, citing precedent and ongoing trials.

Jan 30, 2026

Business

Analysts Bullish on BeOne Medicines: Phase 3 Success Fuels $3.8B Revenue Forecast for 2025

Citizens reiterates a 'Market Outperform' rating and $396 price target for BeOne Medicines (ONC), driven by robust Phase 3 trial results in gastric cancer. The firm highlights the company's strong pipeline and cash position as key growth drivers.

Jan 30, 2026

Business

Stifel Initiates Coverage on Sportradar with Buy Rating, Sees Opportunity in Sports Betting's 'Rational Duopoly'

Analysts at Stifel have initiated coverage on sports data giant Sportradar Group AG (NASDAQ: SRAD) with a Buy rating and a $28 price target, citing its dominant market position and favorable industry dynamics as online sports betting consolidates.

Jan 30, 2026

Business

UBS Sees Stabilization for Globant in 2026, Raises Price Target Amid Mixed Outlook

UBS has increased its price target for digital transformation leader Globant to $75, forecasting a period of stabilized, if modest, growth for the IT services sector next year despite near-term revenue headwinds.

Jan 30, 2026

Business

Stifel Takes Cautious Stance on Genius Sports, Citing 'Picks & Shovels' Edge in Booming Betting Market

Analyst firm Stifel has initiated coverage on sports data giant Genius Sports with a Hold rating, praising its foundational role in the online betting ecosystem but flagging a balanced risk-reward at current levels.

Jan 30, 2026

Business

RBC Lifts Price Target on Ascendis Pharma, Backs Growth Trajectory Through 2026

RBC Capital has reaffirmed its confidence in Ascendis Pharma, raising its price target following the company's ambitious 2026 strategic goals, which hinge on sustained momentum for its lead therapy and significant long-term revenue targets.

Jan 30, 2026

Business

On Holding: A 2026 Growth Story Backed by Analysts Despite Price Target Adjustments

Despite a recent price target cut by KeyBanc, On Holding AG (NYSE: ONON) remains a top growth pick for 2026, with Goldman Sachs upgrading the stock to Buy. Analysts highlight the brand's global momentum and product strength as key drivers.

Jan 30, 2026

Business

Truist Bullish on Amer Sports, Forecasts EPS Above $2.50 by 2030 on Strong Growth Strategy

Truist Securities has raised its price target for Amer Sports (NYSE: AS), citing the company's clear long-term roadmap and 'durable growth levers' across its portfolio of iconic sports brands. The firm sees a realistic path to earnings per share exceeding $2.50 by fiscal 2030.

Jan 30, 2026

World

France Blocks Eutelsat's Ground Antenna Sale, Citing Strategic Sovereignty Concerns

The French government has intervened to stop satellite operator Eutelsat from selling its ground antenna assets, framing the move as a defense of European strategic autonomy against rivals like SpaceX's Starlink.

Jan 30, 2026

Business

The £100k Tax Cliff Edge: How Britain's Stealth Tax Hits High Earners and What They Can Do

A quirk in the UK tax system means those earning between £100,000 and £125,140 face an effective 60% marginal tax rate, while also losing crucial childcare benefits. We examine the growing trap and the financial planning strategies to navigate it.

Jan 30, 2026

Business

China Approves Sciwind's Diabetes Drug Xianyida, Intensifying GLP-1 Market Competition

Sciwind Biosciences secures Chinese approval for its GLP-1 agonist Xianyida, entering a crowded but high-stakes diabetes treatment market dominated by global giants, as the country grapples with the world's largest diabetic population.

Jan 30, 2026

Business

Robert Half Sees Green Shoots in Q4, But Recovery Remains Fragile Amid Year-Over-Year Declines

Robert Half International reports a pivotal return to sequential revenue growth in Q4 2025, signaling a potential turning point after a prolonged slump. However, the staffing giant continues to grapple with significant year-over-year declines, highlighting an uneven recovery path for the broader professional labor market.

Jan 30, 2026

Business

Royal Caribbean Charts Aggressive Expansion on Record Demand, Unveils New Ship Class

Buoyed by record bookings and strong financial performance in 2025, Royal Caribbean Group projects double-digit revenue growth for 2026. The cruise giant announced a major fleet expansion, including a new 'Discovery Class' and ten additional river cruise ships, signaling confidence in sustained consumer appetite for experiential travel.

Jan 30, 2026